Cargando…

Effect of a patient decision aid (PDA) for type 2 diabetes on knowledge, decisional self-efficacy, and decisional conflict

BACKGROUND: Patients with type 2 diabetes (T2DM) often have poor glycemic control on first-line pharmacologic therapy and require treatment intensification. Intensification decisions can be difficult because of many available options and their many benefits and risks. The American Diabetes Associati...

Descripción completa

Detalles Bibliográficos
Autores principales: Bailey, Robert. A., Pfeifer, Michael, Shillington, Alicia C., Harshaw, Qing, Funnell, Martha M., VanWingen, Jeffrey, Col, Nanada
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4712511/
https://www.ncbi.nlm.nih.gov/pubmed/26762150
http://dx.doi.org/10.1186/s12913-016-1262-4
_version_ 1782410078078369792
author Bailey, Robert. A.
Pfeifer, Michael
Shillington, Alicia C.
Harshaw, Qing
Funnell, Martha M.
VanWingen, Jeffrey
Col, Nanada
author_facet Bailey, Robert. A.
Pfeifer, Michael
Shillington, Alicia C.
Harshaw, Qing
Funnell, Martha M.
VanWingen, Jeffrey
Col, Nanada
author_sort Bailey, Robert. A.
collection PubMed
description BACKGROUND: Patients with type 2 diabetes (T2DM) often have poor glycemic control on first-line pharmacologic therapy and require treatment intensification. Intensification decisions can be difficult because of many available options and their many benefits and risks. The American Diabetes Association recommends patient-centered, evidence-based tools supporting shared decision-making between patients and clinicians. We developed a patient decision aid (PDA) targeting decisions about treatment intensification for T2DM. Our objective was to determine the effectiveness of this PDA for patients with T2DM on metformin who require treatment intensification. METHODS: This study was a pragmatic randomized controlled trial conducted in 27 US primary care and endocrinology clinics. Subjects were English-speaking adults with T2DM receiving metformin with persistent hyperglycemia who were recommended to consider medication intensification. Subjects were randomized to receive either the PDA or usual care (UC). Main outcome measures were change in knowledge, decisional self-efficacy, and decisional conflict. RESULTS: Of 225 subjects enrolled, 114 were randomized to the PDA and 111 to UC. Mean [SD] age was 52 [1] years, time since T2DM diagnosis was 6 [+/−6] years, 45.3 % were male, and most (55.5 %) were non-Caucasian. Compared to UC, PDA users had significantly larger knowledge gains (35.0 % [22.3] vs 9.9 % [22.2]; P < 0.0001) and larger improvements in self-efficacy (3.7 [16.7] vs−3.9 [19.2]; P < 0.0001) and decisional conflict (−22.2 [20.6] vs−7.5 [16.6]; P < 0.0001). CONCLUSIONS: The PDA resulted in substantial and significant improvements in knowledge, decisional conflict and decisional self-efficacy. Decisional conflict scores after PDA use were within the range that correlates with effective decision-making. This PDA has the potential to facilitate shared-decision-making for patients with T2DM. TRIAL REGISTRATION: NCT02110979 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12913-016-1262-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4712511
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47125112016-01-15 Effect of a patient decision aid (PDA) for type 2 diabetes on knowledge, decisional self-efficacy, and decisional conflict Bailey, Robert. A. Pfeifer, Michael Shillington, Alicia C. Harshaw, Qing Funnell, Martha M. VanWingen, Jeffrey Col, Nanada BMC Health Serv Res Research Article BACKGROUND: Patients with type 2 diabetes (T2DM) often have poor glycemic control on first-line pharmacologic therapy and require treatment intensification. Intensification decisions can be difficult because of many available options and their many benefits and risks. The American Diabetes Association recommends patient-centered, evidence-based tools supporting shared decision-making between patients and clinicians. We developed a patient decision aid (PDA) targeting decisions about treatment intensification for T2DM. Our objective was to determine the effectiveness of this PDA for patients with T2DM on metformin who require treatment intensification. METHODS: This study was a pragmatic randomized controlled trial conducted in 27 US primary care and endocrinology clinics. Subjects were English-speaking adults with T2DM receiving metformin with persistent hyperglycemia who were recommended to consider medication intensification. Subjects were randomized to receive either the PDA or usual care (UC). Main outcome measures were change in knowledge, decisional self-efficacy, and decisional conflict. RESULTS: Of 225 subjects enrolled, 114 were randomized to the PDA and 111 to UC. Mean [SD] age was 52 [1] years, time since T2DM diagnosis was 6 [+/−6] years, 45.3 % were male, and most (55.5 %) were non-Caucasian. Compared to UC, PDA users had significantly larger knowledge gains (35.0 % [22.3] vs 9.9 % [22.2]; P < 0.0001) and larger improvements in self-efficacy (3.7 [16.7] vs−3.9 [19.2]; P < 0.0001) and decisional conflict (−22.2 [20.6] vs−7.5 [16.6]; P < 0.0001). CONCLUSIONS: The PDA resulted in substantial and significant improvements in knowledge, decisional conflict and decisional self-efficacy. Decisional conflict scores after PDA use were within the range that correlates with effective decision-making. This PDA has the potential to facilitate shared-decision-making for patients with T2DM. TRIAL REGISTRATION: NCT02110979 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12913-016-1262-4) contains supplementary material, which is available to authorized users. BioMed Central 2016-01-14 /pmc/articles/PMC4712511/ /pubmed/26762150 http://dx.doi.org/10.1186/s12913-016-1262-4 Text en © Bailey et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Bailey, Robert. A.
Pfeifer, Michael
Shillington, Alicia C.
Harshaw, Qing
Funnell, Martha M.
VanWingen, Jeffrey
Col, Nanada
Effect of a patient decision aid (PDA) for type 2 diabetes on knowledge, decisional self-efficacy, and decisional conflict
title Effect of a patient decision aid (PDA) for type 2 diabetes on knowledge, decisional self-efficacy, and decisional conflict
title_full Effect of a patient decision aid (PDA) for type 2 diabetes on knowledge, decisional self-efficacy, and decisional conflict
title_fullStr Effect of a patient decision aid (PDA) for type 2 diabetes on knowledge, decisional self-efficacy, and decisional conflict
title_full_unstemmed Effect of a patient decision aid (PDA) for type 2 diabetes on knowledge, decisional self-efficacy, and decisional conflict
title_short Effect of a patient decision aid (PDA) for type 2 diabetes on knowledge, decisional self-efficacy, and decisional conflict
title_sort effect of a patient decision aid (pda) for type 2 diabetes on knowledge, decisional self-efficacy, and decisional conflict
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4712511/
https://www.ncbi.nlm.nih.gov/pubmed/26762150
http://dx.doi.org/10.1186/s12913-016-1262-4
work_keys_str_mv AT baileyroberta effectofapatientdecisionaidpdafortype2diabetesonknowledgedecisionalselfefficacyanddecisionalconflict
AT pfeifermichael effectofapatientdecisionaidpdafortype2diabetesonknowledgedecisionalselfefficacyanddecisionalconflict
AT shillingtonaliciac effectofapatientdecisionaidpdafortype2diabetesonknowledgedecisionalselfefficacyanddecisionalconflict
AT harshawqing effectofapatientdecisionaidpdafortype2diabetesonknowledgedecisionalselfefficacyanddecisionalconflict
AT funnellmartham effectofapatientdecisionaidpdafortype2diabetesonknowledgedecisionalselfefficacyanddecisionalconflict
AT vanwingenjeffrey effectofapatientdecisionaidpdafortype2diabetesonknowledgedecisionalselfefficacyanddecisionalconflict
AT colnanada effectofapatientdecisionaidpdafortype2diabetesonknowledgedecisionalselfefficacyanddecisionalconflict